S&P 500   3,327.73 (+0.64%)
DOW   27,201.52 (+1.39%)
QQQ   270.61 (+0.09%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   449.99 (+0.20%)
CGC   19.26 (-0.31%)
BABA   264.97 (+1.06%)
TSLA   1,485.02 (-0.13%)
MU   51.08 (-0.43%)
GE   6.31 (+2.77%)
AMD   85.31 (+0.32%)
T   29.83 (-0.60%)
F   6.94 (+1.17%)
ACB   10.70 (-0.28%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.24 (+8.48%)
BAC   25.38 (+1.48%)
BA   173.22 (+4.94%)
S&P 500   3,327.73 (+0.64%)
DOW   27,201.52 (+1.39%)
QQQ   270.61 (+0.09%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   449.99 (+0.20%)
CGC   19.26 (-0.31%)
BABA   264.97 (+1.06%)
TSLA   1,485.02 (-0.13%)
MU   51.08 (-0.43%)
GE   6.31 (+2.77%)
AMD   85.31 (+0.32%)
T   29.83 (-0.60%)
F   6.94 (+1.17%)
ACB   10.70 (-0.28%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.24 (+8.48%)
BAC   25.38 (+1.48%)
BA   173.22 (+4.94%)
S&P 500   3,327.73 (+0.64%)
DOW   27,201.52 (+1.39%)
QQQ   270.61 (+0.09%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   449.99 (+0.20%)
CGC   19.26 (-0.31%)
BABA   264.97 (+1.06%)
TSLA   1,485.02 (-0.13%)
MU   51.08 (-0.43%)
GE   6.31 (+2.77%)
AMD   85.31 (+0.32%)
T   29.83 (-0.60%)
F   6.94 (+1.17%)
ACB   10.70 (-0.28%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.24 (+8.48%)
BAC   25.38 (+1.48%)
BA   173.22 (+4.94%)
S&P 500   3,327.73 (+0.64%)
DOW   27,201.52 (+1.39%)
QQQ   270.61 (+0.09%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   449.99 (+0.20%)
CGC   19.26 (-0.31%)
BABA   264.97 (+1.06%)
TSLA   1,485.02 (-0.13%)
MU   51.08 (-0.43%)
GE   6.31 (+2.77%)
AMD   85.31 (+0.32%)
T   29.83 (-0.60%)
F   6.94 (+1.17%)
ACB   10.70 (-0.28%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.24 (+8.48%)
BAC   25.38 (+1.48%)
BA   173.22 (+4.94%)
Log in

NASDAQ:ATXIAvenue Therapeutics Stock Price, Forecast & News

$10.27
-0.08 (-0.77 %)
(As of 08/5/2020 03:56 PM ET)
Add
Compare
Today's Range
$10.14
Now: $10.27
$10.63
50-Day Range
$9.60
MA: $10.41
$11.13
52-Week Range
$4.96
Now: $10.27
$11.83
Volume6,782 shs
Average Volume35,751 shs
Market Capitalization$171.30 million
P/E RatioN/A
Dividend YieldN/A
Beta0.16
Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was founded in 2015 and is based in New York, New York.
Read More
Avenue Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.27 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATXI
CUSIPN/A
Phone781-652-4500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.41 per share

Profitability

Net Income$-25,910,000.00

Miscellaneous

Employees6
Market Cap$171.30 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable
$10.27
-0.08 (-0.77 %)
(As of 08/5/2020 03:56 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATXI News and Ratings via Email

Sign-up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Avenue Therapeutics (NASDAQ:ATXI) Frequently Asked Questions

How has Avenue Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Avenue Therapeutics' stock was trading at $7.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ATXI shares have increased by 38.0% and is now trading at $10.27.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Avenue Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avenue Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Avenue Therapeutics
.

When is Avenue Therapeutics' next earnings date?

Avenue Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020.
View our earnings forecast for Avenue Therapeutics
.

How were Avenue Therapeutics' earnings last quarter?

Avenue Therapeutics Inc (NASDAQ:ATXI) released its quarterly earnings results on Monday, May, 11th. The company reported ($0.08) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.17) by $0.09.
View Avenue Therapeutics' earnings history
.

What price target have analysts set for ATXI?

1 equities research analysts have issued 12 month target prices for Avenue Therapeutics' stock. Their forecasts range from $13.00 to $13.00. On average, they expect Avenue Therapeutics' share price to reach $13.00 in the next twelve months. This suggests a possible upside of 26.6% from the stock's current price.
View analysts' price targets for Avenue Therapeutics
.

Has Avenue Therapeutics been receiving favorable news coverage?

Media coverage about ATXI stock has been trending somewhat negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Avenue Therapeutics earned a coverage optimism score of -1.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the immediate future.
View the latest news about Avenue Therapeutics
.

Are investors shorting Avenue Therapeutics?

Avenue Therapeutics saw a increase in short interest in July. As of July 15th, there was short interest totaling 230,000 shares, an increase of 12.1% from the June 30th total of 205,200 shares. Based on an average trading volume of 64,600 shares, the short-interest ratio is currently 3.6 days. Approximately 3.5% of the shares of the company are short sold.
View Avenue Therapeutics' Current Options Chain
.

Who are some of Avenue Therapeutics' key competitors?

What other stocks do shareholders of Avenue Therapeutics own?

Who are Avenue Therapeutics' key executives?

Avenue Therapeutics' management team includes the following people:
  • Dr. Lindsay Allan Rosenwald, Exec. Chairman (Age 64)
  • Dr. Lucy Lu, Pres, CEO & Director (Age 44)
  • Mr. Joseph Walter Vazzano, CFO, Principal Financial Officer & Company Sec. (Age 35)
  • Dr. Scott A. Reines, Interim Chief Medical Officer (Age 72)

When did Avenue Therapeutics IPO?

(ATXI) raised $30 million in an initial public offering on Tuesday, June 27th 2017. The company issued 5,000,000 shares at $5.00-$7.00 per share. Oppenheimer acted as the underwriter for the IPO and National Securities Corp. was co-manager.

What is Avenue Therapeutics' stock symbol?

Avenue Therapeutics trades on the NASDAQ under the ticker symbol "ATXI."

Who are Avenue Therapeutics' major shareholders?

Avenue Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include National Asset Management Inc. (0.61%), Mackay Shields LLC (0.15%) and UBS Group AG (0.04%). Company insiders that own Avenue Therapeutics stock include Elizabeth Garrett Ingram, Jeffrey Paley, Joseph Walter Vazzano and Neil Herskowitz.
View institutional ownership trends for Avenue Therapeutics
.

Which institutional investors are buying Avenue Therapeutics stock?

ATXI stock was bought by a variety of institutional investors in the last quarter, including Mackay Shields LLC, National Asset Management Inc., and UBS Group AG. Company insiders that have bought Avenue Therapeutics stock in the last two years include Elizabeth Garrett Ingram, Jeffrey Paley, Joseph Walter Vazzano, and Neil Herskowitz.
View insider buying and selling activity for Avenue Therapeutics
.

How do I buy shares of Avenue Therapeutics?

Shares of ATXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Avenue Therapeutics' stock price today?

One share of ATXI stock can currently be purchased for approximately $10.27.

How big of a company is Avenue Therapeutics?

Avenue Therapeutics has a market capitalization of $171.30 million. The company earns $-25,910,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Avenue Therapeutics employs 6 workers across the globe.

What is Avenue Therapeutics' official website?

The official website for Avenue Therapeutics is www.avenuetx.com.

How can I contact Avenue Therapeutics?

Avenue Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected]

This page was last updated on 8/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.